coteauBeta Get App

IMTX

Immatics N.V.
$7.31
-3.05% Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-34%-20%-6%+8%+23%Oct 2025Oct 2026Apr 202652w high $12.4152w low $6.65
IMTXSPY
1W
+8.6%
1M
-15.0%
3M
-19.5%
6M
-35.6%
YTD
-30.4%
1Y
-28.2%

Live chart

Loading live chart…

What they do

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Healthcare · Biotechnology

For information only · Important disclosures

Grades vs sector

No sector grades for IMTX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 5 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

News

More news
Stifel Initiates Immatics at Buy With $15 Price Target
MT Newswires · Oct 14
Nanobiotix Appoints Arnd Christ as CFO
MT Newswires · Oct 01
Immatics and 4 More Stocks See Action From Activist Investors
Barrons.com · Sep 04
Sector Update: Healthcare Stocks Advance Tuesday Afternoon
MT Newswires · Aug 25
Sector Update: Healthcare Stocks Edge Higher Premarket Tuesday
MT Newswires · Aug 25

Key stats

Market value$1.2B
P/E (next 12 months, estimated)-3.8
52-week range$6.65 – $12.41
Revenue growth (latest quarter vs a year ago)+93.0%
Dividend yieldNo dividend
Analyst consensusStrong Buy (7)
Average analyst price target$17.26 (+136%)
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

Earnings

IMTX earningsNext report in 25 days
Next report
Tue Nov 17, 2026Before the open
EPS consensus-$0.50 range -$0.54–-$0.44
Revenue consensus$12.5M 9 analysts
Last 4 quarters · EPS vs estimate
Aug 18, 2026-$0.53est -$0.48−12.1%Below estimates
May 12, 2026-$0.51est -$0.44−15.5%Below estimates
Mar 5, 2026-$0.34est -$0.48+29.2%Above estimates
Nov 17, 2025-$0.49est -$0.45−7.4%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-21 18:29:08 ET
24-1125-0325-0525-0825-1126-0326-0526-08-0.680.45
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$9.1M+93.0%
2026-03-31$7.6M–
2025-12-31$19.8M–
2025-09-30$5.2M–
2025-06-30$4.7M–
Rating changes
Initiated
2026-10-14 · Stifel started covering IMTX at Buy
Reiterated
2026-05-19 · Chardan Capital reiterated Buy on IMTX
Initiated
2026-04-28 · TD Cowen started covering IMTX at Buy
Reiterated
2025-11-24 · Chardan Capital reiterated Buy on IMTX
Reiterated
2025-11-19 · Mizuho reiterated Outperform on IMTX
Reiterated
2025-11-18 · Guggenheim reiterated Buy on IMTX

Third-party analyst actions, not Coteau's views. All rating changes

Insider trades
Perceptive Advisors Llc
Director · 2026-08-26
Buy
$7.5M
None
None · None
Sell
–

Stats refreshed 2026-10-21 18:29:08 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Beta 0.9 · Oct 21, 2026